Immunohistochemical expression of CD44v6 in differentiated thyroid carcinomas
Open Access
- 30 September 2012
- journal article
- Published by Taylor & Francis in Alexandria Journal of Medicine
- Vol. 48 (3) , 241-249
Abstract
CD44 is a polymorphic family of cell surface proteoglycans and glycoproteins implicated in cell-to-cell and cell-to-matrix adhesion interactions and tumor metastasis. This study was designed to histopathologically examine and immunohistochemically detect the expression of CD44v6 in differentiated thyroid carcinomas, and its association with clinicopathologic parameters. Forty different thyroid lesions constituted the material of this study. Cases were divided into a malignant (n = 30) and a non-malignant group (n = 10). Immunostaining was manually performed using CD44v6 mouse monoclonal antibody. CD44v6 expression was significantly higher in malignant compared to non-malignant lesions. This significance was not maintained when cases were categorized as neoplastic and non-neoplastic. Female sex and patients age <45 years were significantly associated with higher CD44v6 expression in the malignant group. Papillary thyroid carcinoma (PTC) showed higher CD44v6 expression than follicular thyroid carcinoma (FTC). CD44v6 immunopositivity did not significantly associate with the microscopic variant of PTC and FTC. Also, tumor size failed to relate significantly with CD44v6 expression within the subtypes of PTC and FTC. However, female sex, patient age <45 years, and tumor size between 1-4cms associated with significantly higher CD44v6 expression in the PTCs when compared to non-malignant lesions. In FTCs no significant relationship was observed between CD44v6 immunopositivity and patients’ age, sex, or tumor size. In the non-malignant group no significant relationship was found between CD44v6 immunopositivity and patients’ sex, or age. The background non-neoplastic thyroid tissue was CD44v6 negative in all cases of both groups except for 4 cases of PTCs. Deregulated expression of CD44v6 occurs in differentiated thyroid carcinomas and in benign thyroid nodules. Thus, further studies are warranted to investigate the diagnostic utility of CD44v6 expression in the differentiation of benign from malignant thyroid lesions. Also, the predictive value of CD44v6 deregulated expression in PTC and the occurrence of nodal metastasis needs further verification.Keywords
This publication has 28 references indexed in Scilit:
- The Immunocytochemistry Is a Valuable Tool in the Diagnosis of Papillary Thyroid Cancer in FNA's Using Liquid-Based CytologyJournal of Oncology, 2010
- CD44 variant isoforms in head and neck squamous cell carcinoma progressionThe Laryngoscope, 2009
- Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusionsDiagnostic Cytopathology, 2007
- Tumor Cells Enhance Their Own CD44 Cleavage and Motility by Generating Hyaluronan FragmentsJournal of Biological Chemistry, 2006
- Immunostaining of galectin‐3 and CD44v6 using fine‐needle aspiration for distinguishing follicular carcinoma from adenomaDiagnostic Cytopathology, 2004
- Immunohistochemical expression of CD44 in thyroid gland lesionsArchive of Oncology, 2003
- Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinomaThe Journal of Pathology, 2000
- Focal Loss of CD44 Variant Protein Expression is Related to Recurrence in Superficial Bladder CarcinomaThe American Journal of Pathology, 1999
- Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomasHistopathology, 1998
- Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55.Journal of Experimental Medicine, 1993